Back to Search
BRETT RAMSEY, PHARMD
PHARMD
Pharmacist
NPI: 1922698018Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
019244(KY)
Research & Publications (20)
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
PMID 19470318·Contemp Clin Trials·2009
4-observational
Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.
PMID 18822427·J Pediatr·2009
8-other
Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression.
PMID 18974024·J Cyst Fibros·2009
8-other
Comparing MSM in the southeastern United States who participated in an HIV prevention chat room-based outreach intervention and those who did not: how different are the baseline HIV-risk profiles?
PMID 17412716·Health Educ Res·2008
8-other
Advancing outcome measures for the new era of drug development in cystic fibrosis.
PMID 17652504·Proc Am Thorac Soc·2007
6-review
Stigma experiences in youth with facial differences: a multi-site study of adolescents and their mothers.
PMID 17552946·Orthod Craniofac Res·2007
4-observational
Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial.
PMID 17685853·Hum Gene Ther·2007
3-trial
Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis.
PMID 17647287·Pediatr Pulmonol·2007
8-other
Outcome measures for development of new therapies in cystic fibrosis: are we making progress and what are the next steps?
PMID 17652503·Proc Am Thorac Soc·2007
6-review
Laboratory parameter profiles among patients with cystic fibrosis.
PMID 16829217·J Cyst Fibros·2007
4-observational
Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
PMID 17534969·Pediatr Pulmonol·2007
8-other
Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients.
PMID 17493132·Mol Microbiol·2007
8-other
Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis.
PMID 17446337·Am J Respir Crit Care Med·2007
3-trial
Use of lung imaging studies as outcome measures for development of new therapies in cystic fibrosis.
PMID 17652502·Proc Am Thorac Soc·2007
6-review
No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.
PMID 17347447·Am J Respir Cell Mol Biol·2007
4-observational
Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis.
PMID 17763333·J Infect Dis·2007
4-observational
Association between pulmonary function and sputum biomarkers in cystic fibrosis.
PMID 17234902·Am J Respir Crit Care Med·2007
4-observational
Respiratory adverse event profiles in cystic fibrosis placebo subjects in short- and long-term inhaled therapy trials.
PMID 16875884·Contemp Clin Trials·2006
8-other
Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa.
PMID 17172450·Proc Natl Acad Sci U S A·2006
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1100 W SHELBY ST
FALMOUTH, KY 41040 - Phone
- (859) 654-3232
Quick Facts
- NPI
- 1922698018
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile